Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts

Assay and Drug Development Technologies

Volumn 5, Issue 3, 2007, Pages 391-401

  Gowan, Sharon M ^a   Hardcastle, Anthea ^a   Hallsworth, Albert E ^a   Valenti, Melanie R ^a   Hunter, Lisa Jane K ^a   De Haven Brandon, Alexis K ^a   Garrett, Michelle D ^a   Raynaud, Florence ^a   Workman, Paul ^a   Aherne, Wynne ^a   Eccles, Suzanne A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOPROTEIN; PROTEIN KINASE B;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE, TUMOR; CHROMONES; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MORPHOLINES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; TRANSPLANTATION, HETEROLOGOUS;

EID: 34447500461     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2006.044     Document Type: Article

References (59)

1. Lewin DA, Weiner MP: Molecular biomarkers in drug development. Drug Discov Today 2004;9:976-983.
2. Workman P: How much gets there and what does it do?: the need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003;9:891-902.
3. Workman P: Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2003;2:131-138.
4. Frank R, Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2:566-580.
5. Collins I, Workman P: Design and development of signal transduction inhibitors for cancer treatment: experience and challenges with kinase targets. Curr Signal Transduc Ther 2006;1:13-23.
6. Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, et al.: Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 2001;7:3544-3550.
7. Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, et al.: Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J Cancer 2005;92:2140-2147.
8. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al.: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-4161.
9. Cummings J, Ward TH, Ranson M, Dive C: Apoptosis pathway-targeted drugs - from the bench to the clinic. Biochim Biophys Acta 2004;1705:53-66.
10. Hardcastle A, Boxall K, Richards J, Tomlin P, Sharp S, Clarke P, et al.: Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90. Assay Drug Dev Technol 2005;3:273-285.
11. Aherne GW, Hardcastle A, Ward E, Dobinson D, Crompton T, Valenti M, et al.: Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules. Clin Cancer Res 2001;7:2923-2930.
12. Basso K, Liso A, Tiacci E, Benedetti R, Pulsoni A, Foa R, et al.: Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 2004;199:59-68.
13. Grimm J, Kirsch DG, Windsor SD, Kim CF, Santiago PM, Ntziachristos V, et al.: Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci USA 2005;102:14404-14409.
14. Kato K, Yamashita R, Matoba R, Monden M, Noguchi S, Takagi T, et al.: Cancer gene expression database (CGED): a database for gene expression profiling with accompanying clinical information of human cancer tissues. Nucleic Acids Res 2005;33:D533-D536.
15. van de Vijver M: Gene-expression profiling and the future of adjuvant therapy. Oncologist 2005;10(Suppl 2):30-34.
16. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Eccles SA, Raynaud FI, Workman P, et al.: Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther 2006;5:187-196.
17. Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P, et al.: Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 2006;5:522-532.
18. Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, et al.: In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005; 11:4875-4887.
19. Cummings J, Ward TH, LaCasse E, Lefebvre C, St-Jean M, Durkin J, et al.: Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 2005;92:532-538.
20. Irish JM, Kotecha N, Nolan GP: Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 2006;6:146-155.
21. Ronzoni S, Faretta M, Ballarini M, Pelicci P, Minucci S: New method to detect histone acetylation levels by flow cytometry. Cytometry A 2005;66:52-61.
22. Chow S, Patel H, Hedley DW: Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 2001;46:72-78.
23. Chung EJ, Lee S, Sausville EA, Ryan Q, Karp JE, Gojo I, et al.: Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry. Ann Clin Lab Sci 2005;35:397-406.
24. Chung EJ, Lee MJ, Lee S, Trepel JB: Assays for pharmacodynamic analysis of histone deacetylase inhibitors. Expert Opin Drug Metab Toxicol 2006;2:213-230.
25. Debad JD, Glezer EN, Wohlstadter JN, Sigal GB, Leland JK: Clinical and biological applications of ECL. In: Electrogenerated Chemiluminescence (Bard AJ, ed.), pp. 43-78. Marcel Dekker, New York, 2004.
26. BioVeris Corp.: http://www.bioveris.com/technology.htm (last accessed on October 20, 20, 2006).
27. Meso Scale Discovery: http://www.mesoscale.com/CatalogSystemWeb/WebRoot/ literature/publications.aspx (last accessed on October 10, 2006).
28. Stimson L, Hardcastle A, Fong P, Gowan S, Drummond A, Davidson A, et al.: Downstream mechanistic markers of HDAC inhibition for drug discovery and clinical evaluation [abstract]. Eur J Cancer Suppl 2006;4:116.
29. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, et al.: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004;23:5853-5857.
30. Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-430.
31. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2: 489-501.
32. Brader S, Eccles SA: Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 2004;90:2-8.
33. Workman P: Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans 2004;32: 393-396.
34. Rogers SJ, Box C, Harrington KJ, Nutting C, Rhys-Evans P, Eccles SA: The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opin Ther Targets 2005;9: 769-790.
35. Powis G, Ihle N, Kirkpatrick DL: Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res 2006;12:2964-2966.
36. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al.: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
37. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al.: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-2559.
38. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, et al.: PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006; 94:247-252.
39. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, et al.: Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006;20:911-928.
40. Burns S, Travers J, Collins I, Rowlands MG, Newbatt Y, Thompson N, et al.: Identification of small-molecule inhibitors of protein kinase B (PKB/AKT) in an Alpha-Screen™ high-throughput screen. J Biomol Screen 2006; 11:822-827.
41. Sabatini DM: mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-734.
42. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000;6:880-886.
43. Semba S, Itoh N, Ito M, Harada M, Yamakawa M: The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenylchromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res 2002;8:1957-1963.
44. Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, Danilin S, et al.: The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 2006;66:5130-5142.
45. Ilan N, Mahooti S, Madri JA: Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 1998;111: 3621-3631.
46. Hwang JH, Hwang JH, Chung HK, Kim DW, Hwang ES, Suh JM, et al.: CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003;88:408-416.
47. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, et al.: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-349.
48. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204.
49. Workman P, Clarke PA, Guillard S, Raynaud FI: Drugging the PI3 kinome. Nat Biotechnol 2006;24:794-796.
50. Sawyers CL: Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010.
51. Finan PM, Thomas MJ: PI 3-kinase inhibition: a therapeutic target for respiratory disease. Biochem Soc Trans 2004; 32:378-382.
52. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al.: A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006;125:733-747.
53. Kim KW, Cho ML, Park MK, Yoon CH, Park SH, Lee SH, et al.: Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther 2005;7:R139-R148.
54. Eason PD, Leta BG, Ly JT, Schaefer LK, Workman SR, Goodwin PJ, et al.: In vivo phosphorylation of key apoptotic and cell survival markers: simultaneous detection of phosphoproteins in a highly specific multiplex assay format. http://www.mesoscale.com/catalogsystemweb/webroot/literature/ applications/pdf/invivophospho.pdf (last accessed October 20, 2006).
55. Pampori N, Eason PD, Ly JT, Leta BG, Schaefer LK, Goodwin PJ, et al.: Multiplex arrays to measure phospho-p38, phospho-Akt and phospho-p53. http://www. mesoscale.com/catalogsystemweb/webroot/literature/applications/pdf/ multiplexarrayphospho.pdf (last accessed October 20, 2006).
56. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, et al.: United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998;77:1-10.
57. Calvert-Evers J, Hammond K: The influence of lysis buffer composition on the expression and activity of protein tyrosine phosphatase. Electrophoresis 2000;21: 2944-2946.
58. Ignatoski KM, Verderame MF: Lysis buffer composition dramatically affects extraction of phosphotyrosine-containing proteins. Biotechniques 1996;20:794-796.
59. Hardcastle A, Cordwell M, Fong P, Stimson L, Workman P, Aherne W: Pharmacodynamic markers of response to novel anticancer agents using a protein profiling sandwich immunoassay format [abstract]. Proc Am Assoc Cancer Res 2006;47.